Positron Emission Tomography-Computed Tomography Imaging for Malignancies in Women

Radiologic Clinics of North America

Volumn 51, Issue 6, 2013, Pages 1111-1125

  Viswanathan, Chitra ^a   Bhosale, Priya R ^a   Shah, Shetal N ^b   Vikram, Raghunandan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cervical cancer; Endometrial cancer; Gynecologic malignancy; PET CT; Pitfalls

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE;

CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; GYNECOLOGIC CANCER; HUMAN; LYMPH NODE METASTASIS; OVARY CANCER; OVARY CARCINOMA; PRIMARY FALLOPIAN TUBE CANCER; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE TUBE DISEASE; VAGINA CANCER; VASCULITIS; VULVA CARCINOMA;

CERVICAL CANCER; ENDOMETRIAL CANCER; GYNECOLOGIC MALIGNANCY; PET/CT; PITFALLS;

DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GENITAL NEOPLASMS, FEMALE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84887176718     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2013.07.006     Document Type: Review

References (50)

1. American Cancer Society Cancer facts & figures 2013 2013, American Cancer Society, Atlanta (GA).
2. Koh W.J., Greer B.E., Abu-Rustum N.R., et al. Cervical Cancer. J Natl Compr Canc Netw 2013, 11:320-343.
3. Gaffney D.K., Erickson-Wittmann B.A., Jhingran A., et al. ACR Appropriateness Criteria® on Advanced Cervical Cancer Expert Panel on Radiation Oncology-Gynecology. Int J Radiat Oncol Biol Phys 2011, 81:609-614.
4. Siegel C.L., Andreotti R.F., Cardenes H.R., et al. ACR Appropriateness Criteria® pretreatment planning of invasive cancer of the cervix. JAm Coll Radiol 2012, 9:395-402.
5. Kidd E.A., Siegel B.A., Dehdashti F., et al. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007, 110:1738-1744.
6. Yen T.C., Lai C.H., Ma S.Y., et al. Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer. Eur J Nucl Med Mol Imaging 2006, 33:1399-1407.
7. Chung H.H., Jo H., Kang W.J., et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007, 104:529-534.
8. Tran B.N., Grigsby P.W., Dehdashti F., et al. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol 2003, 90:572-576.
9. Bader A.A., Winter R., Haas J., et al. Where to look for the sentinel lymph node in cervical cancer. Am J Obstet Gynecol 2007, 197:678.e1-678.e7.
10. Havrilesky L.J., Kulasingam S.L., Matchar D.B., et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005, 97:183-191.
11. Sironi S., Buda A., Picchio M., et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology 2006, 238:272-279.
12. Wright J.D., Dehdashti F., Herzog T.J., et al. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-d-glucose-positron emission tomography. Cancer 2005, 104:2484-2491.
13. Zand B., Euscher E.D., Soliman P.T., et al. Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol 2010, 119:422-425.
14. Grigsby P.W., Siegel B.A., Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. JClin Oncol 2001, 19:3745-3749.
15. Singh A.K., Grigsby P.W., Dehdashti F., et al. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys 2003, 56:489-493.
16. Schwarz J.K., Siegel B.A., Dehdashti F., et al. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007, 298:2289-2295.
17. Birlik M., Akar S., Tuzel E., et al. Gemcitabine-induced vasculitis in advanced transitional cell carcinoma ofthe bladder. JCancer Res Clin Oncol 2004, 130:122-125.
18. Howlader N., Noone A.M., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2008 2011, National Cancer Institute, Bethesda (MD).
19. Harries M., Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002, 3:529-536.
20. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. NEngl J Med 2006, 354:34-43.
21. Sugarbaker P.H. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer. Curr Opin Obstet Gynecol 2009, 21:15-24.
22. Podoloff D.A., Ball D.W., Ben-Josef E., et al. NCCN task force: clinical utility of PET in a variety of tumor types. JNatl Compr Canc Netw 2009, 7(Suppl 2):S1-S26.
23. Morgan R.J., Alvarez R.D., Armstrong D.K., et al. NCCN clinical practice guidelines in oncology: epithelial ovarian cancer. JNatl Compr Canc Netw 2011, 9:82-113.
24. Javitt M.C. ACR Appropriateness Criteria on staging and follow-up of ovarian cancer. JAm Coll Radiol 2007, 4:586-589.
25. Kitajima K., Suzuki K., Senda M., et al. FDG-PET/CT for diagnosis of primary ovarian cancer. Nucl Med Commun 2011, 32:549-553.
26. Hubner K.F., McDonald T.W., Niethammer J.G., et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol 1993, 51:197-204.
27. Rieber A., Nussle K., Stohr I., et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol 2001, 177:123-129.
28. Risum S., Hogdall C., Loft A., et al. The diagnostic value of PET/CT for primary ovarian cancer-a prospective study. Gynecol Oncol 2007, 105:145-149.
29. Kurokawa T., Yoshida Y., Kawahara K., et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 2004, 109:926-932.
30. Fenchel S., Grab D., Nuessle K., et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002, 223:780-788.
31. Simcock B., Neesham D., Quinn M., et al. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006, 103:271-276.
32. Chung H.H., Kang W.J., Kim J.W., et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007, 34:480-486.
33. Mangili G., Picchio M., Sironi S., et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 2007, 34:658-666.
34. Thrall M.M., DeLoia J.A., Gallion H., et al. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007, 105:17-22.
35. Salani R., Backes F.J., Fung M.F., et al. Posttreatment surveillance and diagnosis of recurrence in womenwith gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011, 204:466-478.
36. Bhosale P., Peungjesada S., Wei W., et al. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer 2010, 20:936-944.
37. Gu P., Pan L.L., Wu S.Q., et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 2009, 71:164-174.
38. Hillner B.E., Siegel B.A., Shields A.F., et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. JNucl Med 2008, 49:1928-1935.
39. Lee J.H., Dubinsky T., Andreotti R.F., et al. ACR Appropriateness Criteria® pretreatment evaluation and follow-up of endometrial cancer of the uterus. Ultrasound Q 2011, 27:139-145.
40. Kitajima K., Murakami K., Yamasaki E., et al. Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. AJR Am J Roentgenol 2008, 190:1652-1658.
41. Picchio M., Mangili G., Samanes Gajate A.M., et al. High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging. Nucl Med Commun 2010, 31:506-512.
42. Kitajima K., Murakami K., Kaji Y., et al. Spectrum of FDG PET/CT findings of uterine tumors. AJR Am J Roentgenol 2010, 195:737-743.
43. Kitajima K., Murakami K., Yamasaki E., et al. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Ann Nucl Med 2008, 22:103-109.
44. Belhocine T., De Barsy C., Hustinx R., et al. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002, 29:1132-1139.
45. Lin L.L., Grigsby P.W., Powell M.A., et al. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. Int J Radiat Oncol Biol Phys 2005, 63:500-504.
46. Cohn D.E., Dehdashti F., Gibb R.K., et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol 2002, 85:179-184.
47. Lamoreaux W.T., Grigsby P.W., Dehdashti F., et al. FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys 2005, 62:733-737.
48. Makhija S., Howden N., Edwards R., et al. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002, 85:53-58.
49. Patel P.V., Cohade C., Chin B.B. PET-CT localizes previously undetectable metastatic lesions in recurrent fallopian tube carcinoma. Gynecol Oncol 2002, 87:323-326.
50. Yun M., Cho A., Lee J.H., et al. Physiologic 18F-FDG uptake in the fallopian tubes at mid cycle on PET/CT. JNucl Med 2010, 51:682-685.